New York, USA – September 30, 2022 – Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, Creative Proteomics Cytokine announced the launch of the Human Luminex Array Platform, which enables simultaneous analysis of multiple cytokines, chemokines, and other protein biomarkers in human serum, plasma, and cell culture samples.
Cytokine arrays are capable of measuring the levels of many proteins simultaneously. Compared to single-target ELISA, immunoprecipitation, or western blot analysis, cytokine array analysis offers greater efficiency, speed, and detection range. Creative Proteomics Cytokine has developed a variety of cytokine arrays that allow for the simultaneous detection and accurate quantification of secreted proteins (cytokines, chemokines, growth factors, etc.) and biomarkers, providing solutions for the comprehensive study of secreted protein factors in biological models, disease mechanisms, and biological systems.
The Luminex xMAP technology involves coupling highly specific capture monoclonal antibodies to different fluorescently labeled magnetic beads, mixing different types of beads, and suspending them in a 96-well microtitration plate. The Luminex technology provides accurate and reproducible results for each metric, requiring only a small amount of samples and at a lower cost, thereby successfully accessing data more effectively than the other assays.
The Luminex multiplex assay utilizes xMAP microbead-based technology to simultaneously detect and quantify multiple secreted proteins, including cytokines, chemokines and growth factors. The Luminex system of Creative Proteomics Cytokine produces results comparable to traditional assays, such as ELISA and qPCR, but with greater efficiency and throughput. In addition, extensive valuable insights into gene expression and protein pathways were achievable by measuring a greater number of data points from a single sample.
Advantages of Creative Proteomics’s Human Luminex Array Platform:
1. High throughput and speed: Analyze fluorescence at speeds of 5,000-15,000 pcs/s. Simultaneous real-time, qualitative and quantitative analysis of multiple different target molecules within the same sample can be performed in less than 3 hrs.
2. High sensitivity: The detection range can reach 3-5 orders of magnitude, and the lowest detection concentration can reach 0.1pg/mL.
3. High specificity and accuracy: The homogeneous immunoassay does not require washing, reducing experimental errors caused by washing during operation. The assay uses flow-through laser technology to detect each microsphere, preventing interference from heterogeneous antigens (antibodies) in the specimen.
“The quantitative analysis of soluble proteins is widely used in immunology, neurobiology, oncology, metabolism and other fields. Compared to traditional ELISA techniques, microsphere-based multiplex assays allow for the simultaneous detection of multiple biomarkers within a single sample, greatly improving research efficiency and enabling high-throughput analysis of rare and valuable samples,” stated Creative Proteomics’s senior scientist.
About Creative Proteomics
Creative Proteomics is an innovative contract research organization that focuses on using advanced equipment platforms and optimized detection technology to help researchers around the world reduce time and costs. The company has a proprietary laboratory information management system to strengthen laboratory quality monitoring and quality management to ensure the efficiency and security of customer data.